Navigation Links
The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer

COLD SPRING HARBOR, N.Y., Sept. 1 /PRNewswire/ -- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available online now at and appear in the September issue of the publication.

"It is important that the breast cancer community rest assured that ODAC is an independent, unbiased panel of experts in oncology whose mission is to provide their best objective scientific and clinical recommendations to the FDA for drug approval," said ODAC Chair, Wyndham Wilson, MD, PhD. Dr. Wilson is Chief of the Lymphoid Therapeutics Section of the Center for Cancer Research, National Cancer Institute.

Bevacizumab is currently approved in combination with paclitaxel for the first-line treatment of advanced HER2-negative breast cancer, based on encouraging results of the E2100 trial (N Engl J Med 357:2666-2676, 2007). The FDA provisionally granted accelerated approval but requested confirmatory data from the manufacturer, Genentech. In November 2009, Genentech supplied the results of the AVADO (J Clin Oncol 28:3239-3247, 2010) and RIBBON-1 trials (J Clin Oncol 27(abstract 1005), 2009). On July 20, 2010, ODAC recommended against conversion to full approval.

Joanne Mortimer, MD, a member of ODAC, who voted to approve bevacizumab in advanced breast cancer in December 2007 based on the E2100 study, said, "The additional data from AVADO and RIBBON-1 supported an increased response rate, but also confirmed the increased toxicity and lack of survival advantage with bevacizumab. Like the majority of panel [ODAC] members, I could not recommend approval." Dr. Mortimer is Director of the Women's Cancers' Program and Professor of Medical Oncology and Experimental Therapeutics at City of Hope Comprehensive Cancer Center in Duarte, CA.

Gabriel Hortobagyi, MD, who attended the ODAC meeting as a consultant to Genentech, said "There is an urgent need for the FDA and the cancer community to agree upon exactly what qualifies a drug for approval." Dr. Hortobagyi is Professor of Medicine and Chairman, Department of Breast Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, TX. "There would certainly be differences of opinion from the various corners as to the requisite degree of benefit," he added, but "by having this conversation we should arrive at what is commensurate with the expectations for advanced breast cancer."

"If we only accepted cancer treatments that improve survival, we would severely limit options for our patients," said Edith P. Perez, MD, Director of the Breast Cancer Program and Professor of Medicine at Mayo Clinic in Jacksonville, FL.

A decision by FDA on bevacizumab's breast cancer indication is expected later this year.

About The ASCO Post

The ASCO Post is a newspaper intended for everyone with an interest in oncology. The ASCO Post serves a broad audience of oncology professionals and covers a wide scope of topics, including clinical cancer research, policy developments, and oncology practice issues. As a benefit of membership, the print edition is distributed to all U.S. ASCO members.  U.S. and international ASCO members also receive complimentary online access.  In addition, non-ASCO member medical oncologists, hematologists, and hematologist/oncologists in the United States will be eligible for a complimentary subscription.

About Harborside Press

Harborside Press is a medical publishing company based in Cold Spring Harbor, New York. Its leadership and management team has more than 50 years of experience in the field, including extensive success in building and leading editorial teams for a number of publications.  Harborside Press is the current publisher of JNCCN--The Journal of the National Comprehensive Cancer Network and The Journal of the Advanced Practitioner in Oncology. Harborside Press publishes The ASCO Post under a license arrangement with the American Society of Clinical Oncology.  For more information on Harborside Press, please visit

SOURCE Harborside Press
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
3. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
4. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
5. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
6. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
7. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
8. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
9. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I ... an inventor from Hillside, N.J. "Many people catch diseases simply from sitting on ... will always be protected from germs." , He developed the patent-pending QUDRATECS to ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):